UVB preferred for treatment of moderate to severe psoriasis

February 24, 2012
UVB preferred for treatment of moderate to severe psoriasis
Ultraviolet B is preferred by dermatologists for first-line treatment of moderate to severe psoriasis in both healthy male and female patients, according to a study published in the March issue of the Journal of the American Academy of Dermatology.

(HealthDay) -- Ultraviolet B (UVB) is preferred by dermatologists for first-line treatment of moderate to severe psoriasis in both healthy male and female patients, according to a study published in the March issue of the Journal of the American Academy of Dermatology.

Joy Wan, of the University of Pennsylvania in Philadelphia, and colleagues surveyed 1,000 U.S. dermatologists, including members of the National Psoriasis Foundation and members of the American Academy of Dermatology who treat psoriasis patients; 387 dermatologists (39 percent) responded.

The researchers found that dermatologists preferred the following therapies for moderate to severe psoriasis for male and , respectively: UVB (40 and 56 percent), (15 and 19 percent), methotrexate (16 and 4 percent), and adalimumab (12 and 10 percent). Among respondents, 66 percent administered phototherapy in their practice. After adjusting for all physician variables, those who preferred first-line UVB for male and female patients were significantly more likely to have phototherapy in their practice (odds ratio [OR], 3.4 and 2.8, respectively) and to have used UVB in more than 10 patients in the last three months (OR, 8.0 and 9.6, respectively). in the Midwest were more likely than those in the Northeast to prefer as first-line therapy for moderate to severe psoriasis for male and female patients.

"UVB is most commonly preferred as a first-line treatment for moderate to severe psoriasis in healthy adults, and preferences vary based on region, phototherapy availability, and prior treatment use," the authors write.

Several authors disclosed to pharmaceutical companies.

Explore further: Evaluation of pediatric psoriasis outpatient health care delivery finds some treatment variability

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Recommended for you

The 'love hormone' may quiet tinnitus

September 23, 2016

(HealthDay)—People suffering from chronic ringing in the ears—called tinnitus—may find some relief by spraying the hormone oxytocin in their nose, a small initial study by Brazilian researchers suggests.

Bile acid uptake inhibitor prevents NASH / fatty liver in mice

September 21, 2016

Drugs that interfere with bile acid recycling can prevent several aspects of NASH (nonalcoholic steatohepatitis) in mice fed a high-fat diet, scientists from Emory University School of Medicine and Children's Healthcare of ...

New therapeutic target for Crohn's disease

September 20, 2016

Research from the Sanford Burnham Prebys Medical Discovery Institute (SBP) identifies a promising new target for future drugs to treat inflammatory bowel disease (IBD). The study, published today in Cell Reports, also indicates ...

Mosquitoes, Zika and biotech regulation

September 19, 2016

In a new Policy Forum article in Science, NC State professor Jennifer Kuzma argues that federal authorities are missing an opportunity to revise outdated regulatory processes not fit for modern innovations in biotechnology, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.